Share this article
Share this article
NEW YORK, May 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of
BELLUS Health Inc. ("BELLUS" or the "Company") (NASDAQ: BLU). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether BELLUS Lidar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On July 6, 2020, Bellus provided investors with an update regarding its product BLU-5937 , in development as a treatment for chronic cough. Bellus announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked. Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed.
Related Keywords
New York ,United States ,Paris ,France General ,France ,Chicago ,Illinois ,Los Angeles ,Abrahaml Pomerantz ,Roberts Willoughby ,Nasdaq ,Pomerantz Firm ,Bellus Health Inc ,Pomerantz Llp ,புதியது யார்க் ,ஒன்றுபட்டது மாநிலங்களில் ,பாரிஸ் ,பிரான்ஸ் ஜநரல் ,பிரான்ஸ் ,சிகாகோ ,இல்லினாய்ஸ் ,லாஸ் ஏஞ்சல்ஸ் ,ராபர்ட்ஸ் விருப்பம் ,நாஸ்டாக் ,போமேரதண்தஜ் நிறுவனம் ,மணி ஆரோக்கியம் இன்க் ,போமேரதண்தஜ் ல்ப் ,
comparemela.com © 2020. All Rights Reserved.